Hasil Pencarian - Timothy Yap

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

    618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L... oleh Syed Kazmi, Lijun Sun, Angela Alistar, Ezra Cohen, Timothy Yap, Devalingam Mahalingam, Justin C Moser, Edward Garmey, Teresa Mooneyham

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center

    397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center oleh Sanjay Gupta, Vivek Subbiah, Sapna Patel, Adi Diab, Ravi Murthy, Aung Naing, Funda Meric-Bernstam, Filip Janku, Alda Tam, Timothy Yap, Rahul Sheth

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

    866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors oleh Chang Liu, Manish Patel, Gerald Falchook, Patricia LoRusso, Timothy Yap, Melissa Johnson, Kristy Kuplast-Barr, Ryan Abo, Erika Manyak, Lisa Cleary, Viviana Bozon, Sudha Parasuraman, Heike Keilhack, Kristen McEachern

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

    287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanc... oleh Yi Liu, Capucine Baldini, Jameel Muzaffar, David Hong, Olivier Rixe, Christophe Massard, Timothy Yap, Solmaz Sahebjam, Ursa Brown-Glaberman, Andreea Varga, Sergey Efuni, Barbara Kapelan, Eniola Ogunmefun, Tomonori Tayama, Henry Zhao, Denis Healy, Robert Latek, Daisuke Nakashima, Emrullah Yilmaz

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: